In 2025, the total market size for Huntington’s disease treatment across seven major markets—the United States, the UK, Japan, and the EU4—reached approximately USD 320 million. The United States currently leads this landscape, bolstered by 44,000 prevalent cases and a high uptake of established therapies like Austedo, which captured USD 167 million in revenue last year.

Industry analysts anticipate that the shift from palliative care to genetic intervention will define the next decade. Major pharmaceutical players, including Skyhawk Therapeutics, PTC Therapeutics, and UniQure, are advancing candidates such as SKY-0515, Votoplam, and AMT-130. These therapies leverage RNA-targeting platforms and gene-silencing technologies to address the underlying cause of the neurodegenerative disorder rather than merely managing chorea or psychiatric symptoms. While the absence of a cure and the heterogeneity of disease progression remain significant clinical hurdles, the integration of predictive genetic screening and increased research funding is expected to accelerate the commercialization of these precision medicines.